Immuno-Oncology | Specialty

PD-1 Targeted Antibody Lambrolizumab Receives FDA Breakthrough Designation

April 25th 2013

Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.

Dutch Researcher Focuses on Fc Signaling in Targeting CD20

April 25th 2013

Jeanette H.W. Leusen, PhD, focuses on studying the working mechanisms of therapeutic antibodies and the biology of fragment crystallizable receptors, including the anti-CD20 monoclonal antibody rituximab in patients with non-Hodgkin lymphoma.

The Effect of Ipilimumab on Health-Related Quality of Life in Patients With Unresectable Advanced Melanoma

April 11th 2013

Patients diagnosed with melanoma are typically affected psychologically. Researchers summarized health-related quality of life (HRQOL) during the 12-week ipilimumab induction period in previously treated patients diagnosed with advanced stage III or IV melanoma.

Dr. Crawford on Sipuleucel-T in Advanced Prostate Cancer

April 5th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.

The Economic Value of Ipilimumab as a Second-Line Treatment in Patients With Advanced Melanoma

April 3rd 2013

Analysis of the cost-effectiveness of ipilimumab compared with best supportive care in previously treated patients with advanced (unresectable or metastatic) melanoma.

AGS-003 Vaccine Achieves Survival Benefits in mRCC

March 26th 2013

AGS-003, a personalized dendritic cell immunotherapy, demonstrated prolonged survival benefits in patients with metastatic renal cell carcinoma, with one-third of those who took the drug during a phase II trial still alive after nearly four years.

Dr. Gomella on Sequencing Prostate Cancer Therapies

March 25th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

Novel Oncolytic Virus Effective in Melanoma

March 22nd 2013

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.

Dr. Petrylak on Sipuleucel-T Delaying First Opioid Use

March 21st 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on Combination Therapies in Prostate Cancer

March 20th 2013

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Dr. Slovin on Prostate Cancer Immunotherapy Evolution

March 18th 2013

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

Dr. Antonarakis on Sequencing ADT and Sipuleucel-T

March 7th 2013

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

Dr. Kandalaft on an Ovarian Cancer Immunotherapy

March 5th 2013

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Dr. Cooperberg on Earlier Treatment With Sipuleucel-T

February 16th 2013

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Dr. Oh on Combination Therapy in Prostate Cancer

January 8th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

Dr. Gettinger on Lung Cancer Immunotherapies

January 8th 2013

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer

December 21st 2012

Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival

A Nobel Prize in Waiting: Understanding Unexpected and Prolonged Remissions

December 19th 2012

Ipilimumab provides a striking example of the way in which some patients derive long-term benefits from therapy while others do not. The reasons for such differences should be a priority for translational research.

Dr. Gettinger on PD-1 Inhibitor BMS-936558 in NSCLC

December 11th 2012

Scott Gettinger, MD, from the Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with NSCLC and other solid tumors.

Dr. Renier Brentjens on Genetically-Modified T Cells

November 21st 2012

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, explains the process by which his laboratory at MSKCC genetically modifies immune cells to fight cancer.